3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Papillomavirus Infections
1
Lymphoma
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Breast Neoplasms
1
Bradycardia
1
Arrhythmias, Cardiac
1
Apnea
1
Interventions
Sorafenib
121
Nivolumab
36
pembrolizumab
32
Bevacizumab
28
lenvatinib
27
Doxorubicin
23
Radiosurgery
21
Radiofrequency Ablation
20
Oxaliplatin
20
Hepatectomy
18
Fluorouracil
15
Capecitabine
15
Magnetic Resonance Spectroscopy
14
atezolizumab
13
Leucovorin
13
Cisplatin
13
Gemcitabine
11
Erlotinib Hydrochloride
11
tislelizumab
9
Sirolimus
9
Radiotherapy
9
Irinotecan
9
Ipilimumab
9
cabozantinib
8
Liver Transplantation
8
regorafenib
7
Ramucirumab
7
Folfox protocol
7
Embolization, Therapeutic
7
sintilimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Hepatocellular
×
Atropine
×
Clear all
NCT00575523
2008-01-25
atropinePEI
Medical University of Vienna
Phase 4
Completed
31 enrolled